Table 1.
Baseline Demographic and Clinical Characteristics of Study Participants (N = 20)
| Characteristic | n (%) or median (range) |
|---|---|
| Age in years | 36 (26–48) |
| Race | |
| African American | 19 (95) |
| White | 1 (5) |
| HIV risk factor | |
| Heterosexual sex | 19 (95) |
| Unknown | 1 (5) |
| Years of HIV diagnosis | 9 (1–17) |
| Nadir CD4 cell count (cells/µL) | 110 (2–320) |
| Most recent CD4 cell count (cells/µL) | 412 (71–1189) |
| <200 | 2 (10) |
| 200–500 | 12 (60) |
| >500 | 6 (30) |
| ART history | |
| Months since first ART regimen | 90 (9–115) |
| Months on current ART regimen | 14 (3–41) |
| Sexually active in past 6 mo | 17 (85) |
| 1 sexual partner | 16 (94) |
| 2 sexual partners | 1 (6) |
| Partner HIV negative | 12 (71) |
| Current hormonal contraceptive use | 1 (5)a |
| Genital infections at screeningb | |
| Gonorrhea | 0 |
| Chlamydia | 0 |
| Syphilis | 2 (10) |
| HSV2 IgG positive | 19 (95) |
| Candida on Gram stain | 5 (25) |
| Bacterial vaginosis from vaginal Gram stain | 5 (25) |
| Dysplasia by most recent Pap smear | 5 (25) |
| Treatment of vaginal infection within 30 d | 6 (30) |
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; HSV2, herpes simplex virus type 2; IgG, immunoglobin G.
a Depot medroxyprogesterone acetate.
b Women with bacterial vaginosis by Amsel criteria, trichomonas or vaginal candidiasis by wet mount, abnormal vaginal discharge, or genital ulcers at screening visit were excluded.